Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Tenofovir Alafenamide Fumarate

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,977Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Apotex's Generic Emtricitabine;TAF Receives Approval in the U.S.
    Apotex's Generic Emtricitabine;TAF Receives Approval in the U.S.

    17 May 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214053

    FDA
    17 May 2024
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Bictegravir Sodium, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets
    FDA Confirms Paragraph IV Patent Litigation for Bictegravir Sodium, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets

    20 Nov 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-bictegravir-sodium-emtricitabine-and-tenofovir-alafenamide-fumarate-tablets-80375.pdf

    FDA
    20 Nov 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Emtricitabine and Tenofovir Alafenamide Fumarate Tablets
    FDA Confirms Paragraph IV Patent Litigation for Emtricitabine and Tenofovir Alafenamide Fumarate Tablets

    14 Dec 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-emtricitabine-and-tenofovir-alafenamide-fumarate-tablets-96673.pdf

    FDA
    14 Dec 2022
    Share Share
    ViiV Healthcare presents three-year switch data for Dovato
    ViiV Healthcare presents three-year switch data for Dovato

    29 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210929005348/en

    BUSINESSWIRE
    29 Sep 2021
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Odefsey 208351 (Emtricitabine, Rilpivirine Hydrochloride and Tenofovir Alafenamide Fumarate )Tablets
    FDA Confirms Paragraph IV Patent Challenge of Odefsey 208351 (Emtricitabine, Rilpivirine Hydrochloride and Tenofovir Alafenamide Fumarate )Tablets

    07 Jan 2020

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-odefsey-208351-emtricitabine-rilpivirine-hydrochloride-and-tenofovir-alafenamide-fumarate-tablets-1578398200.pdf

    FDA
    07 Jan 2020
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Descovy 208215 (Emtricitabine and Tenofovir Alafenamide Fumarate) Tablets
    FDA Confirms Paragraph IV Patent Challenge of Descovy 208215 (Emtricitabine and Tenofovir Alafenamide Fumarate) Tablets

    07 Jan 2020

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-descovy-208215-emtricitabine-and-tenofovir-alafenamide-fumarate-tablets-1578411210.pdf

    FDA
    07 Jan 2020
    Share Share